17,261 trials
Leukemia
Primary: Maximum Tolerated Dose of Intensity-modulated Radiotherapy (Phase I) — 2000 cGy
Carcinoma, Non-Small-Cell Lung · Carcinoma, Small Cell Lung · Carcinoma, Thymic
Primary: Percentage of Enrolled Participants Testing Positive for Genomic Abnormality — 28.5; 44.2; 0; 24.9 percentage of participants
Chronic Thromboembolic Pulmonary Hypertension
Primary: Number of Participants With Treatment-emergent Adverse Events (TEAEs) — 72 Participants
COVID-19 · ARDS
Primary: Evaluation of 60-day Mortality Rate — 10; 14; 16 Participants — p=0.1343
Fragile x Syndrome
Primary: Clinical Global Impression-Improvement (CGI-I) Scale — 3.4; 3.5 Scores on a scale — p=0.4475
Sialorrhoea
Primary: Saliva Secreted Rate — -6.508; -34.512; 83.695; 7.414 percentage of change from baseline
Relapsed/Refractory Multiple Myeloma
Primary: Number of Participants With Adverse Events — 6; 9; 6; 9 Participants
Metastatic Prostate Cancer · Pain
Primary: Percentage of Participants With 30% Decline in the Brief Pain Inventory (BPI) Worst Pain Item From Baseline to Week 8 — 11 Percentage of pts w/pain improvement
Glioblastoma
Primary: Objective Response Rate (ORR) — 1; 3 Participants
COVID-19
Primary: Number of Participants Requiring Mechanical Ventilation or Dying — 3; 3 Participants
Head and Neck Cancer
Primary: Overall Response — 28 Participants
Rheumatoid Arthritis
Primary: Change From Baseline (BL) in Disease Activity Score (DAS)28-C Reactive Protein (CRP) at Week 12 — -2.65; -2.35; -2.30; -2.20 Units on a scale — p=0.0158
Malignant PEComa
Primary: Objective Overall Response Rate (ORR) — 2; 10; 16; 3 Participants
Stage IV Non-Small Cell Lung Cancer
Primary: Progression Free Survival — 3.5; 9.7 months — p=.01
Obstructive Sleep Apnea
Primary: Apnea-Hypopnea Index (AHI)4% Events Per Hour — 28.6; 26.6 events/hour